Magazine article Clinical Psychiatry News

CGRP-Targeted Migraine Prevention Drugs Pass Phase II

Magazine article Clinical Psychiatry News

CGRP-Targeted Migraine Prevention Drugs Pass Phase II

Article excerpt

FROM THE AAN 2014 ANNUAL MEETING

Two investigational migraine prevention drugs that target a vasodilating peptide significantly decreased the number of migraine days per month, compared with placebo, during a pair of phase II studies.

Both drugs reduced mean migraine headache days per month by more than 4 days overall.

Each is a monoclonal antibody that inhibits calcitonin gene-related peptide (CGRP). The antibodies could be game changers for migraine patients, Dr. Peter Goadsby said in an interview.

"Here are the first mechanism-based preventive treatments for migraine," said Dr. Goadsby of the University of California, San Francisco. "They are easy to use, biweekly or even monthly injections, which are effective and well tolerated."

During the annual meeting of the American Academy of Neurology, Dr. Goadsby presented the findings on ALD403, developed by Alder Biopharmaceuticals. His colleague Dr. David W. Dodick of the Mayo Clinic, Rochester, Minn., presented findings on LY2951742, which is being developed by Arteaus Therapeutics in conjunction with Eli Lily.

The trial of ALD403 comprised 163 patients who experienced 5T4 migraine headache days per month; 81 were randomized to receive a single infusion of 1,000 mg ALD403 and the rest received placebo. Patients were followed for 24 weeks. Patients in the active treatment group fared significantly better than those in the placebo group, with a mean reduction in migraine headache days of -5.6, compared with -4. …

Search by... Author
Show... All Results Primary Sources Peer-reviewed

Oops!

An unknown error has occurred. Please click the button below to reload the page. If the problem persists, please try again in a little while.